$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

$ALPHAMAB-B (09966.HK)$ If corning & Jerry's late-stage data can validate the early-stage data, it means that first-line treatment of NSCLC(MOS estimated at more than 25 months in phase II) can obtain MOS data much higher than K

$ALPHAMAB-B (09966.HK)$ $KINTOR PHARMA-B (09939.HK)$ $INNOVENT BIO (01801.HK)$ Today Hong Kong pharmaceutical and biotech stocks fell 2.36%, industry groups in Hong Kong or top 5, kill the biological medicine market valuation, capital is still wary of innovative drug, exploit medicine, corning jerry that is called a fall, but has strong industry leading cinda biology, growth of 4.16% in the pharmaceutical sector in the first, Market money still likes and likes a few big champions.

$ALPHAMAB-B (09966.HK)$ Recist 41.9% and MRECist 60.5%, so 046 ORR may have a slight advantage, but the sample size is small